FDA Cracks Down on Black Market Peptides

The U.S. Food and Drug Administration (FDA) has initiated a significant crackdown on the burgeoning black market for peptides. The agency recently issued warning letters to five U.S.-based companies for allegedly selling unapproved peptide-based drugs. These companies are accused of illegally marketing weight loss products, including unauthorized versions of Eli Lilly's retatrutide and Novo Nordisk's semaglutide (known as Wegovy and Ozempic).,

The implicated companies also offered copycat versions of various other therapeutics, including muscle-boosting and libido-enhancing drugs. Although these companies claimed their products were for laboratory research only, the FDA found evidence indicating they were intended for human use. The agency highlighted the significant public health risks associated with unregulated injectable products entering the bloodstream.,

In a parallel development, an FDA advisory board recently voted to ease restrictions on peptides. This decision could pave the way for specialized pharmacies to offer multiple peptide treatments without requiring full clinical testing. This move aims to address the growing public interest in peptides for aesthetic improvements, such as muscle tone and fat distribution.